Table 3.
TNF group (n=20) | Non-TNF group (n=36) | p value | ||
---|---|---|---|---|
Viral infectionsa | Total no. of infections | 24 | 42 | |
No. of subjects affected | 12 (60 %) | 22 (61 %) | 1.00 | |
Gastrointestinal infections | Total no. of infections | 8 | 8 | |
No. of subjects affected | 5 (25 %) | 5 (14 %) | 0.47 | |
Skin and soft tissue infectionsb | Total no. of infections | 2 | 6 | |
No. of subjects affected | 2 (10 %) | 5 (14 %) | 1.00 | |
Upper respiratory tract infectionsc | Total no. of infections | 11 | 20 | |
No. of subjects affected | 8 (40 %) | 12 (33 %) | 0.77 | |
Lower respiratory tract infectionsd | Total no. of infections | 4 | 3 | |
No. of subjects affected | 4 (20 %) | 3 (8 %) | 0.23 | |
Total infections overall | 49 | 79 | ||
Total no. of subjects with ANY infection overall | 15 (75 %) | 29 (81 %) | 0.74 |
Includes influenza in 3 non-TNF subjects (versus 0 TNF subjects)
Includes localized herpes zoster infection in 1 non-TNF subject (versus 0 TNF subjects)
Includes ear, sinus, and throat infections
Includes bronchitis and pneumonia